A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

Published:2012-10-11 Issue:1 Volume:71 Page:93-101
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Plummer Ruth,Madi Ayman,Jeffels Melinda,Richly Heike,Nokay Bahar,Rubin Stephen,Ball Howard A.,Weller Steve,Botbyl Jeffrey,Gibson Diana M.,Scheulen Max E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-012-1982-z

Reference21 articles.

1. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068

2. van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886

3. Altorki N, Lane ME, Bauer T et al (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28:3131–3137

4. Bible KC, Suman VJ, Molina JR et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962–972

5. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119:32–37

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

2. Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases;Drugs in Context;2023-08-14

3. Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine;Frontiers in Pharmacology;2023-03-07

4. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?;Cancers;2023-03-03

5. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management;Expert Opinion on Drug Metabolism & Toxicology;2022-01-02